Lung Transplant HCV, Pilot Study

NCT03112044 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Lung Transplant Infection
Hepatitis C

Interventions

DRUG: Sofosbuvir-velpatasvir (400 mg/100 mg)
DEVICE: Ex Vivo Lung Perfusion (EVLP)

Sponsor

University Health Network, Toronto

Collaborators

[object Object]